Architects behind Celgene takeout step down as Flagship adds another industry vet in Biondi

With the departure of BMS's Head of Strategy and BD Paul Biondi to Flagship Pioneering, two of the main executives behind the pharma's acquisition of Celgene have now stepped down. Robert Hershberg departed as EVP, head of BD and global alliances at Celgene earlier this month; he did not respond to inquiries regarding his next role.

Bristol-Myers Squibb Co. (NYSE:BMY) completed its $74 billion acquisition of Celgene Corp. on Nov. 20 (see "Bristol-Myers' Next Phoenix Act?")...